About Epstein-Barr virus-associated infectious mononucleosis

Article

Although the Epstein-Barr virus causes most illnesses presenting as mononucleosis, clinicians should be able to recognize and consider alternate differential possibilities.

Recent Videos
Image credit: Production Perig
Paul Kruszka, MD
Herbert Bravo, MD
Tina Tan, MD
Paul Kruszka, MD, MPH, FACMG
Stephanie Anne Deutsch, MD, MS, MSCR, FAAP
H. Westley Phillips, MD
David Turkewitz, MD
H. Westley Phillips, MD
Related Content
Pediatric RSV vaccine trial enrollment on hold in US, VRBPAC says | Image Credit: © kitsawet - © kitsawet - stock.adobe.com.

Pediatric RSV vaccine trial enrollment on hold in US, VRBPAC says

Joshua Fitch, Senior Editor
December 12th 2024
Article

The halt follows a severe respiratory disease safety signal observed in a July 2024 phase 1 trial of Moderna's mRNA-1345 and mRNA-1365 vaccine candidates.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
COVID-19 Therapy Roundtable: Focusing on Inpatient Care | Image credit: Production Perig

COVID-19 Therapy Roundtable: focusing on inpatient care

Joshua Fitch, Senior Editor ;John Parkinson
December 11th 2024
Article

In this episode, the panel discusses therapies and care around inpatients including mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and remdesivir.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
Using a smartphone application to screen for neonatal jaundice | Image Credit: © zilvergolf - © zilvergolf - stock.adobe.com.

Using a smartphone application to screen for neonatal jaundice

Joshua Fitch, Senior Editor
December 11th 2024
Article

A good correlation and statistical agreement with total serum bilirubin was observed in a study of a new smartphone-based machine learning app, leaving it a potential neonatal jaundice screening tool.

Upadacitinib effective in treating atopic dermatitis through 76 weeksLatest revision | Image Credit: © Rochu_2008 - © Rochu_2008 - stock.adobe.com.

Upadacitinib effective in treating atopic dermatitis through 76 weeks

Joshua Fitch, Senior Editor
December 10th 2024
Article

In the study through 76 weeks, no new risks were observed with once-daily upadacitinib (15 mg or 30 mg).

© 2024 MJH Life Sciences

All rights reserved.